Articles tagged with Multiple Myeloma
A new study has identified ADAR1 as a key factor in suppressing the immune response triggered by lenalidomide, leading to drug resistance in multiple myeloma. The research suggests targeting ADAR1 and the dsRNA pathway could offer promising strategies to overcome resistance.
Researchers found that NSD2 helps maintain MM cell identity by reorganizing DNA and influencing gene activity. This discovery could shape future treatment approaches for patients with t(4;14) myeloma.
Researchers found that pomalidomide enhances key immune cells, such as T cells and natural killer cells, which helps the body recognize and destroy cancer cells. This leads to improved immune profiles in patients with myeloma, resulting in longer progression-free survival periods.
Researchers developed sicXer, a mesoporous silica-collagen xerogel that mimics mineralized collagen and promotes bone healing. BoXer, a drug-loaded version of sicXer, releases anti-myeloma medication locally at bone lesions, demonstrating potential for stabilization and healing of fracture-prone bones.
Sylvester Comprehensive Cancer Center offers expert advice on coping with holiday loss and grief. Biological age can predict early colorectal cancer risk, while research advances may lead to a cure for multiple myeloma. Blood cancer experts share insights into new treatments.
A new treatment shows promise for people with high-risk smoldering multiple myeloma, delaying cancer progression and improving overall survival. Daratumumab significantly reduces risk of progression to active disease and improves patient outcomes.
A new review published in Blood Cancer Discovery outlines how research supported a recent FDA committee decision to allow minimal residual disease as an endpoint for accelerated approval in multiple myeloma. This decision could cut a decade off the drug development process, enabling faster innovation in cancer treatment.
Researchers are working to develop a curative treatment for multiple myeloma by combining treatments, overcoming resistance, and tailoring therapy to individual patients. The study found promising results using bispecific antibodies in combination with other treatments.
Researchers from the Sylvester Comprehensive Cancer Center presented their findings on the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes. Dr. Stephen D. Nimer received the 2024 ASH Mentor Award for his impact on hematology trainees.
Researchers developed a single-cell RNA-sequencing atlas of the Multiple Myeloma immune microenvironment across disease stages. The atlas reveals potential resistance mechanisms and identifies conventional dendritic cells as a targetable population in MM.
A new technique called Clonal competition assays helps understand the evolutionary advantages of multiple myeloma cells over available treatments. It allows researchers to see how each population of cells in the same myeloma reacts to treatments, getting closer to understanding heterogeneity and resistance.
Researchers identified a subgroup of multiple myeloma patients with an epigenetic alteration in the PVR gene, which results in improved immune response to immunotherapy. This new test can help clinicians predict patient outcomes and tailor treatment strategies.
A study published in Blood reported high response rates of 89% and complete responses of 70% among patients with relapsed or refractory multiple myeloma who received cilta-cel infusions. The results were comparable to those seen in clinical trials, suggesting the therapy's effectiveness in real-world settings.
A Cleveland Clinic study found delayed time to treatment with oral antimyeloma medications, particularly among Black and elderly patients. Independent predictors identified include barriers to timely medication prescription fill.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
This review explores the key signaling pathways driving multiple myeloma and highlights their potential as therapeutic targets, including PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways.
A Spanish research study has described the composition of the immune system in blood samples from patients with multiple myeloma and found that altered immune cells influence vaccine efficacy. The study reveals a more severe immune suppression in patients with multiple myeloma compared to those with other tumors.
A blood test measures lymphocyte count to predict treatment response in relapsed multiple myeloma. Patients with higher lymphocyte counts experience better cancer control for longer periods.
Researchers identify key proteins and signaling pathways for personalized treatment, enabling early detection of aggressive tumors. The study provides a crucial resource for developing new therapies and tests to guide treatment.
Quadruple therapies offer deeper responses and longer clinical benefits for patients with newly diagnosed multiple myeloma. The addition of an immunotherapy agent to the backbone of small molecule drugs may improve overall survival and reduce the need for bone marrow transplants.
The FDA committee voted unanimously to approve minimal residual disease (MRD) as a new clinical endpoint for evaluating proposed drugs to treat multiple myeloma. A meta-analysis led by C. Ola Landgren shows a strong correlation between MRD and clinical outcomes in newly diagnosed and relapsed patients.
Researchers at Goethe University Frankfurt have discovered thalidomide derivatives that target and degrade BCL-2, a protein essential for the survival of cancer cells. The derivatives bind to CRBN, reprogramming its binding surface to mark BCL-2 for degradation, ultimately leading to cell death.
Researchers at the University of Leipzig Medical Center have identified biomarkers associated with the response to CAR T cell therapy in multiple myeloma. These biomarkers enable patients to predict their likelihood of responding well or less well to treatment before initiating therapy.
A recent study by the University of California - Davis Health found that racial and social barriers significantly impact access to autoHCT, a key bone marrow transplant treatment for multiple myeloma. Despite having higher rates of cancer development compared to other groups, Black patients received lower proportions of the transplant ...
A study found that structural racism is largely to blame for disparities in tuberculosis (TB) incidence among the U.S.-born population. Researchers analyzed national TB registry data and found that TB incidence ratios were higher for certain racial and ethnic groups, with greater relative disparities among females.
Researchers at RCSI have identified a new treatment option for multiple myeloma by combining venetoclax with 5-azacytidine. This combination shows enhanced efficacy across various patient samples and has the potential to expand treatment options for those resistant to standard care.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
Researchers have developed a new immunotherapy based on STAb cells that outperforms existing CAR-T treatment in laboratory trials. The new therapy recruits natural T cells to fight cancer cells and overcomes limitations of current treatments.
Researchers develop a novel genomic classification system that categorizes patients into 12 distinct groups based on their underlying genomic profiles. The individualized risk model, IRMMa, uses advanced statistical methodologies to generate tailored predictions of patient response to different therapies.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
Researchers found decreased BMAd density and altered distribution profile in MGUS patients who developed MM, indicating early changes in bone marrow adipose tissue. These findings suggest the potential for timely interventions and personalized treatment strategies.
Researchers discovered a connection between hepatitis B and C viruses and multiple myeloma, finding that antiviral treatment can improve outcomes. The study suggests that early detection of these infections may lead to better treatment and survival rates for patients with this cancer.
A new study from Sylvester Comprehensive Cancer Center suggests that prophylactic treatment can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. This approach could eliminate hospital stays and broaden access to immunotherapy treatments for more cancer patients.
Researchers at Mass General Brigham have developed a new class of proteasome inhibitors that specifically target the β2 active site in cancer cells. The newly synthesized compounds effectively inhibit multiple myeloma cell growth and show promise for reducing therapeutic resistance and side effects when combined with existing drugs.
A new study in mice shows that a hybrid treatment combining a drug and a protein fragment can prevent the growth of blood cancer cells by targeting the RAS gene mutation. The treatment, which blocks cell division and multiplication, has shown promising results in live animals with multiple myeloma tumors.
Researchers found that tumour cells escape immunotherapy by losing or changing BCMA and GPRC5D targets on their surface. This understanding has led to the suggestion of periodically profiling myeloma cells throughout a patient's treatment course to adapt treatment strategies.
A new study found that ide-cel, a CAR T-cell therapy, showed similar survival outcomes for Black and white patients with multiple myeloma. Researchers hope this finding encourages the use of ide-cel in all patients with multiple myeloma.
A study published in Blood Advances found that diabetes is associated with poorer survival rates in white patients with multiple myeloma, but not Black patients. Researchers believe higher insulin levels may accelerate cancer growth.
A retrospective analysis of 37 heavily pretreated multiple myeloma patients found that intravenous immunoglobulin (IVIg) reduced the risk of severe infections by 90%. Patients with hypogammaglobulinemia experienced a higher rate of severe infections, and IVIg supplementation significantly mitigated this risk.
Researchers found that patients' immune systems play a vital role in determining the duration of remission from multiple myeloma. Sustained minimal residual disease (MRD) negativity is associated with prolonged survival, with patients achieving MRD negativity for at least two years remaining free from multiple myeloma 10 years later.
Researchers at the University of Miami Miller School of Medicine identified distinct genomic events responsible for resistance to anti-BCMA and anti-GPRC5D immunotherapies in multiple myeloma. Mutations in the extracellular domain of BCMA impede T-cell binding without affecting protein expression or downstream signaling.
A new oral agent called mezigdomide has shown impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies. The treatment produced a response rate of over 40% and a median duration of response of almost 8 months.
A multicenter team has identified three risk biomarkers for chronic graft-versus-host-disease, which can be measured at 90 days after transplantation. These markers include MMP3, DKK3, and CXCL9, which are associated with fibrosis, inflammation, and immune cell attraction.
A breakthrough treatment targeting bone marrow cancer cells destroyed 90% of multiple myeloma cells in laboratory tests and 60% in human tissue samples. Researchers developed lipid-based nanoparticles containing RNA molecules that silence the CKAP5 gene, inhibiting cancer cell division.
Researchers have created an RNA nanoparticle therapy that disables the pathways through which multiple myeloma cells travel, stopping their spread. The therapy targets the microenvironment of the cancer and prevents the production of a protein that attracts cancer cells to blood vessels.
Researchers at MD Anderson Cancer Center develop new methodology to analyze earliest precursor stages of multiple myeloma, revealing substantial genomic and transcriptional heterogeneity. The study identifies potential therapeutic targets and biomarkers for high-risk patients.
Researchers developed a calculator to identify patients with multiple myeloma and primary systemic amyloidosis who have a more benign profile, allowing for personalized treatment. The tool predicts survival based on clinical-biological characteristics and has been validated in international series.
A study found that clinical trial eligibility criteria may be a barrier to enrollment of patients from underrepresented racial and ethnic groups. Black patients were most likely to be deemed ineligible due to blood cell counts or lack of prior treatments, while Asian patients had the lowest rate of ineligibility.
Researchers at ETH Zurich have developed a new method called pharmacoscopy to test treatment options for multiple myeloma patients. This high-throughput screening platform analyzes the reactions of cancer cells to various treatments, offering personalized therapeutic strategies.
A Phase I and Phase II clinical trial of the immunotherapy REGN5459 resulted in a 90.5 percent overall response rate among patients with relapsed multiple myeloma. The treatment is reasonably tolerated, with common side effects including cytokine release syndrome.
A phase 3 clinical trial shows that motixafortide combined with standard therapy increases the number of stem cells that can be harvested in over 92% of patients. The combination also enhances the collection of primitive stem cells, which have greater potential for reconstituting blood cell types.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Two novel genetically defined mouse models replicate two subtypes of human multiple myeloma, revealing the interaction of genetic aberrations as a key factor in development. The models will aid in identifying specific therapeutic strategies for individualized treatment.
Researchers found that FABP5 is linked to more aggressive disease and poorer survival in multiple myeloma. Patients with higher FABP5 expression had significantly shorter time to disease progression and overall survival.
A new study found that patients with recurrent multiple myeloma can benefit from receiving ide-cel CAR T therapy earlier in their disease course. The treatment showed a nearly sevenfold increase in complete remission rates compared to standard care.
Scientists at MIT have designed a novel nanoparticle platform that can deliver optimal ratios of multiple cancer drugs, leading to enhanced efficacy and reduced side effects. The bottlebrush-shaped particles can be loaded with varying concentrations of drugs, enabling the precise delivery of synergistic combinations.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Modakafusp alfa has shown significant potential in combating multiple myeloma with 43% of patients experiencing a partial response. The treatment targets interferon in cells expressing CD38, a marker present on myeloma cells and immune cells.
Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.
Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.